Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFrom approval to your kitchen counter: how the Wegovy pill works in practice
Step one: understanding what the Wegovy pill actually is
Start with the ingredient. The Wegovy pill in the UK is oral semaglutide, the same GLP-1 receptor agonist found in the familiar weekly pen, formulated with a substance called SNAC that helps the stomach absorb it. Novo Nordisk makes both. So when people ask "is Wegovy a pill now?", the honest answer is that the medicine hasn't changed character, only its delivery.
Semaglutide works by mimicking a natural gut hormone. It slows how quickly the stomach empties and turns down appetite signals, which is why many people feel fuller for longer and eat less without white-knuckling it. That mechanism is well documented across the wider semaglutide programme, and the NHS medicines guide to semaglutide sets out the basics plainly.
What is genuinely new is the format. Until summer 2026, weight-loss semaglutide in the UK meant an injection. The tablet gives an oral route for the first time, which matters to anyone who dislikes needles or simply wants a pen-free option. If you want the fuller background on the launch and licensing, our page on Wegovy as a pill covers the ground in detail.
One thing to keep straight: this is the weight-loss tablet, not a diabetes product. Rybelsus is also oral semaglutide but is licensed for type 2 diabetes at different strengths. Muddling the two is easy, and we untangle it on our Rybelsus semaglutide tablets page.
Step two: how the tablet is actually taken each morning
The routine is specific, and it is worth getting right. You take the tablet first thing in the morning on an empty stomach, with a small sip of plain water, up to roughly 120ml. Then you wait at least 30 minutes before eating, drinking anything else including coffee, or taking other oral medicines. Swallow it whole.
That 30-minute gap isn't fussiness. Oral semaglutide is absorbed in a narrow window, and food or other drinks in the stomach blunt how much gets through. Picture it before the kettle has even boiled: tablet, sip of water, then the wait while the day gets going. Get that rhythm settled and it becomes automatic.
Storage is refreshingly low-maintenance. Unlike the pen, the tablets sit at room temperature, so there is no fridge shelf to negotiate and travel is straightforward. For anyone who has juggled a chilled pen through airport security, that alone is a draw.
A question our prescribers hear most weeks is whether you can just double up if you forget a day. You can't, and you shouldn't guess. Missed doses, timing tweaks and any changes to the schedule are decisions for your prescriber, guided by the patient information leaflet. We keep the practical detail of the routine on our oral Wegovy page for people who like the specifics.
Step three: the dose ladder from 1.5mg to 25mg
Wegovy tablets do not start at full strength. Treatment begins at 1.5mg, then steps up through 4mg and 9mg to the 25mg maintenance dose, with a minimum of one month at each level. That gradual climb exists to let your system settle and to keep early side effects manageable rather than to treat you from day one.
People already established on the 2.4mg weekly injection may be able to move directly onto the 25mg tablet, though that is always subject to a clinical assessment rather than an assumption. It is not a like-for-like swap you can arrange yourself.
Here is a point worth pinning down, because it trips people up. The weight-loss tablet ladder runs 1.5mg, 4mg, 9mg and 25mg only. The 3mg, 7mg and 14mg tablet strengths belong to Rybelsus, the diabetes product, and are not rungs on the Wegovy weight-loss schedule. If you have seen a 7mg semaglutide tablet mentioned, that is the diabetes strength, not a Wegovy weight-loss dose. We keep the two ladders clearly separated across our Wegovy tablets pages so no one ends up confused about which strength does what.
Because dosing is titrated and personal, we don't publish a dose to "take". The exact schedule, and whether any of it fits you, is a prescriber's call.
Step four: who the Wegovy pill in the UK is licensed for
The tablet is licensed for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition, used together with a reduced-calorie diet and more physical activity. Weight-related conditions here include things such as prediabetes, high blood pressure, raised cholesterol and obstructive sleep apnoea.
Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance, so the number alone isn't the whole story. Neither is BMI in general. Our prescribers look at your health picture as a whole, and meeting a threshold on paper never guarantees that treatment is right for you.
Some groups are not suitable. The pill is not recommended in pregnancy, while breastfeeding, or if you are trying to conceive, and it is not licensed for anyone under 18. A history of certain thyroid or pancreatic conditions also needs a proper conversation before anything is prescribed.
If you would like to sense-check where you stand before going further, the eligibility outline on our weight-loss treatments page runs through the licensed criteria and what a consultation involves. It is the same clinical bar whether you are asking about the tablet or the pen.
Step five: what the trial evidence shows about the tablet
The headline evidence comes from OASIS 4, a phase 3 trial of 307 adults with obesity, or overweight plus at least one weight-related condition, who did not have diabetes. Over 64 weeks, alongside lifestyle changes, participants taking oral semaglutide lost about 13.6% of their body weight on average, compared with roughly 2.4% on placebo.
Among people who stayed fully adherent to treatment throughout the trial, average loss reached around 17%. That fuller figure is real, but it describes committed adherence rather than the plain average, which is why the 13.6% number is the fairer everyday expectation. Results in a trial are also not a promise for any individual.
These figures put the tablet in striking territory. It brings an oral option meaningfully close to what people have come to associate with the injections, without the pen. You can read more about the study design on our Wegovy pill trial page if the numbers interest you.
The most common side effects in the trial were gastrointestinal, reported by around 74% of the tablet group versus about 42% on placebo, and were generally mild to moderate and short-lived. That pattern echoes the wider semaglutide evidence base rather than being unique to the tablet.
Step six: side effects and when to seek help
Most side effects sit in the stomach and gut. Nausea, an unsettled stomach, constipation, reflux, tiredness and headaches are the ones people notice most, and they tend to be at their peak soon after starting or after a dose increase, often easing within days to a couple of weeks. The gradual dose ladder is designed partly to soften that landing.
Some signs need prompt attention rather than patience. Severe stomach pain that spreads to the back, with or without vomiting, can point to pancreatitis, which the MHRA flagged as an uncommon but serious risk in a 2026 safety update covering GLP-1 medicines. Gallbladder symptoms, signs of dehydration from prolonged sickness, and any allergic reaction also warrant medical help.
You can report a suspected side effect through the MHRA's Yellow Card scheme, which also collects reports about suspicious sellers. It is a quick, worthwhile thing to know about before you start any GLP-1 treatment.
If you take an oral contraceptive, it is worth raising with your prescriber. The absorption-effect advice differs between semaglutide and tirzepatide, and the interaction between Wegovy and the mini pill is a sensible thing to check rather than assume.
Step seven: NHS availability, cost context and how to get it
At launch, the Wegovy pill is not available on the NHS. A NICE appraisal would need to happen first, so for now it is a private prescription only. That mirrors how new weight-loss medicines usually reach patients before any NHS route opens.
On cost, private weight-loss treatment in the UK is priced per month and varies by provider and dose. Any legitimate price should include the clinical assessment and prescription, not just the medicine, and headline figures often leave out consultation, delivery and aftercare. We are deliberately not the cheapest option, and we think that is the right trade for a genuine supply chain and real clinical oversight. Current tablet pricing sits on our treatment page, and we set out the fuller picture on Wegovy pill price.
Getting it, legitimately, means a prescription following a clinical assessment. With nume, a real prescriber reviews your consultation the same day, we verify your identity and weight, and treatment is dispensed from our GPhC-registered UK pharmacy. You can confirm any online pharmacy on the GPhC register before you buy anywhere, which is the single best check against fake pens and tablets sold online without a clinical assessment.
Related questions we've answered
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.